SCHEMBL2409528

SCHEMBL2409528

COc1ccc(CC(=O)c2c(O)c3cccnc3n(-c3ccccc3)c2=O)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 3/20 0.46
MAPT P10636 2/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 2/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
MAPK8 P45983 1/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALOX12 P18054 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
POLB P06746 1/20 0.41
FEN1 P39748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414794 0.87 PTGDR2 (0.46) HPGDMAPTHTTLMNAMAPK8
SCHEMBL2409299 0.87 TOP2A (0.49) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL2409859 0.87 FEN1 (0.42) MEN1KMT2AMAPTGAAMAPK8
SCHEMBL2409603 0.85 FEN1 (0.43) MEN1KMT2AMAPTMAPK8POLB
SCHEMBL2407463 0.85 LIPG (0.45) MEN1KMT2AMAPTGAAMAPK8
SCHEMBL2409456 0.85 PDE1A (0.51) MAPTTSHRMAPK8ALDH1A1CYP2C19
SCHEMBL2411153 0.83 MAPT (0.40) MEN1KMT2AMAPTGAAHTT
SCHEMBL2408715 0.82 CNR2 (0.47) MAPTTSHRALDH1A1CYP2C19FEN1
SCHEMBL2414348 0.82 RECQL (0.49) MEN1KMT2AMAPTGAAMAPK8
SCHEMBL2409205 0.82 FEN1 (0.43) MEN1KMT2AMAPK8FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A MEN1 4691/4885KMT2A 3171/4885HPGD 169/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A MEN1 4719/4885KMT2A 3015/4885HPGD 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.